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Suicide and the Dexamethasone Suppression Test 
in Adolescence 
Douglas R. Robbins and Norman E. Alessi 
The identification and treatment of adolescents 
at risk for suicide is one of the most critical 
issues in adolescent psychiatry. Suicide is the 
third leading cause of death in the age group 
and its prevalence appears to be rising (Holin- 
ger, 1978). Clinicians see many adolescents with 
suicidal thoughts or behavior, however, who are 
not all equally at risk for future lethal attempts. 
While demographic, diagnostic, and other clin- 
ical factors are helpful in identifying adolescents 
at risk for suicide (Carlson and Cantwell 1982; 
Garfinkle et al. 1982; Robbins and Alessi 1983) 
such factors remain limited in their ability to 
identify individuals at greatest risk (Pokorny 
1983). A biological marker of current or future 
risk for suicide could be an important adjunct 
to the clinician confronting this dilemma. Fur- 
thermore, study of biological markers may help 
us towards an understanding of the neurophys- 
iological substrates of severe dysphoric mood 
states. 
Carroll (1982) has reported an association of 
nonsuppression in the dexamethasone suppres- 
sion test (DST) with severe or lethal suicide 
attempts in adults. Three other groups also ob- 
served DST nonsuppression in patients hospi- 
talized for suicide attempts or who subsequently 
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made lethal or potentially lethal attempts (Cor- 
yell and Schlesser 1982; Targum et al. 1983; 
Banki and Arato 1982). Others have reported 
high urinary free cortisol in lethal suicide at- 
tempts (Ostroffet al. 1983). CSF cortisol levels, 
however, did not distinguish suicidal patients in 
one earlier study (Bunney et al. 1969). This 
study presents preliminary observations of the 
DST as a possible biological correlate of suicide 
in adolescents. 
M e t h o d  
All adolescents (13-18 years) admitted to the 
inpatient unit of the University of Michigan Ad- 
olescent Psychiatry Service are evaluated by two 
child psychiatrists with the Schedule for Affec- 
tive Disorders and Schizophrenia (SADS), 
Hamilton Depression Rating Scale, and Carroll 
Depression Self-Rating Scale, and all are given 
a diagnosis according to the Research Diagnos- 
tic Criteria (RDC) and DSM-III. All those not 
excluded for medical reasons are given a dex- 
amethasone suppression test (DST), using 1 mg 
oral dexamethasone at 11:30 PM on day 1, with 
blood samples for cortisol at 11:00 on day 1 and 
at 8:00 AM, 4:00 aM, and 11:00 PM on day 2. 
Cortisol is assessed by competitive protein bind- 
ing radioimmunoassay (Pierson-Murphy 1967). 
Cortisol values over 5 p,g/ml in any sample on 
day 2 are considered abnormal. In this popu- 
lation, the DST has been abnormal in 44% of 
those with Major Depressive Disorder, endog- 
enous subtype, and in none with other diagnoses 
(Robbins et al. 1983). 
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Suicide attempts and ideation are investi- 
gated in the clinical evaluation and the SAI~S 
interview. The SADS item for "Medical Le- 
thality" of suicide attempts is defined as follows: 
1 ("No d a n g e r . . ,  held pills in hand"), 2 
("Minimal, e.g., scratch on wrist"), 3 ("Mild, 
e.g., took 10 aspirins"), 4 ( "Modera t e . . .  
brief unconsciousness"), 5 ("Severe, e.g., cuts 
throat"), 6 ("Extreme, e.g., respiratory arrest"). 
Attempts were rated as being medically dan- 
gerous if they received a rating of 4 to 6 on 
this SADS item. 
R e s u l t s  
Of 45 adolescents evaluated, 23 had attempted 
suicide. The ages, sex, diagnoses, SADS Med- 
ical Lethality, and DST results are presented in 
Table 1. Of those with suicidal behavior, four 
made medically dangerous attempts (SADS 
Medical Lethality = 4-6). The results are sum- 
marized by category of suicidal behavior and 
DST results in Table 2. All six of those with 
DST nonsuppression attempted suicide on ad- 
mission, while 17 of the 22 with normal DSTs 
Table 1. Age, Sex, Diagnosis, Suicidal Medical Lethality, and DST Results 
of Patients Attempting Suicide 
DST cortisol values 
DSM III SADS 
Patient number Age Sex Axis I Diagnosis Medical Lethality ~ I 1:00 8:00 4:00 11:00 
1 17 M MD-Mei 5 1.72 1.37 1.55 7.49 
Atypical BPD 
2 16 M MD-Mel 6 2.15 18.42 5.61 2.43 
3 17 M MD-Mel 5 I 1.42 7.03 7.19 4.58 
4 17 F MD-Mel 4 16.28 6.94 - -  7.90 
5 16 M MD 2 3.09 4.20 4.38 3.42 
6 14 M MD i 1.72 1.65 1.56 1.44 
CD, soc., 
nonagg. 
7 13 F MD-Mel 1 7.26 1.17 1.17 1.03 
8 16 M MD 2 2.07 2.03 1.55 1.18 
O-CD 
9 16 F MD-Mel 2 10.86 1.09 0.59 8.42 
10 16 M DD 3 3.90 1.43 - -  0.52 
11 14 F DD 1 - -  0.91 0.68 0.27 
12 16 M MD-Mel 1 3.99 - -  1.01 2.36 
13 14 F MD-Mel 1 1.11 1.11 1.34 0.92 
Psychotic 
14 16 M MD 3 1.09 - -  1.90 1.55 
15 16 F MD-Mel 2 2.48 8.54 1.16 1.39 
Atypical BPD 
16 16 F MD 2 0.72 0.43 0.34 0.68 
17 17 F S-P 1 2.29 2.69 2.49 1.51 
18 16 F MD 1 3.75 0.87 0.83 1.78 
19 14 F MD 3 2.70 2.03 1.57 1.32 
20 16 F MD-Mel 2 3.00 1.48 1.20 1.42 
21 12 F CD, sot., I 2.31 3.73 3.06 2.87 
nonagg. 
22 12 M MD 3 - -  0.58 0.64 - -  
23 17 M S-P 1 3.86 0.93 0.99 2.71 
°See text for definitions of SADS Medical Lethality ratings. 
Atypical BPD = Atypical Bipolar Disorder; CD = Conduct Disorder; DD = Dysthymic Disorder; MD = Major Depression; 
MD-Mel = Major Depression-Melancholic; nonagg. = nonaggressive; O ~ D  = Obsessive-Compulsive Disorder; soc. = socialized; 
S-P = Schizophrenia-Paranoid. 
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Table 2. Suicidal Behavior and DST Results 
DST DST 
suppressors nonsuppressors 
Suicidal behavior 17 6 
Lethal attempt 0 1 
Potentially lethal attempt 0 3 
Nonlethal attempt 17 2 
No suicidal behavior 22 0 
had attempted suicide. The association of sui- 
cide attempts with DST nonsuppression was sig- 
nificant (×2 = 6.622, df = 1, p < 0.01). 
Of those who attempted suicide, four of the 
six nonsuppressors made medically dangerous 
or lethal attempts, while none of the 17 sup- 
pressors made such severe attempts. This sta- 
tistic suggests a highly significant association of 
DST nonsuppression with lethal or potentially 
lethal suicidalbehavior(x 2 =  13.719, df = 1, 
p < 0.0002). 
It should be noted that two patients admitted 
for non-medically serious attempts were found 
to have nonsuppression, and subsequently made 
medically serious attempts---one fatal. The oth- 
ers making medically serious attempts had made 
those attempts just prior to admission. 
Discussion 
The number of adolescents studied is relatively 
small (n = 45) and must be replicated with a 
larger population, but these observations may 
have important implications. These observa- 
tions extend to the critical adolescent age group 
the preliminary findings by others that there may 
be an identifiable dysfunction of the hypo- 
thalmic-pituitary-adrenal axis associated with 
severe dysphoric states in which individuals may 
be seriously suicidal (Carroll 1982; Coryell and 
Schlesser 1982; Targum et al. 1983; Ostroff et 
al. 1983; Banki and Arato 1982). 
Because of the current controversy regarding 
the diagnostic specificity of the DST and be- 
cause of the preliminary nature of all the re- 
ported associations of the DST with suicidal 
behavior, the clinical utility of these findings 
must be considered uncertain. They raise the 
possibility, however, that an abnormal DST may 
prove useful as a marker of increased potential 
for suicide. It should be noted that two subjects 
with nonsuppression on the DST initially made 
suicidal attempts that were medically not seri- 
ous, but later went on to make serious attempts, 
one fatal; this suggests that the DST might iden- 
tify individuals at higher risk at a point when 
clinical features alone would not so clearly iden- 
tify them. Larger studies are clearly needed to 
establish whether such clinical applications are 
justified. Separately from the possible clinical 
utility of the marker, further study is needed to 
clarify whether or not the DST helps us under- 
stand the pathophysiology of severe dysphoric 
mood states. 
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Are There Antibodies Against Brain in Sera 
from Schizophrenic Patients? 
Review and Prospectus 
Lynn E. DeLisi, Richard J. Weber, Candace B. Pert 
Introduction 
An autoimmune basis to neuropsychiatric dis- 
orders was first proposed during the early 1900s 
(Khoroshko 1912). The subsequent search for 
circulating autoantibodies in sera and cerebro- 
spinal fluid (CSF) from schizophrenic patients 
has resulted in numerous published relxnls, some 
of which confirm and others of which fall to 
find support for this hypothesis. 
As early as 1937, Lehmann-Facius described 
evidence for the presence of circulating anti- 
brain antibodies in sera from schizophrenic pa- 
tients, specifically to antigens unique to post- 
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mortem schizophrenic brain (Lehmann-Facius, 
1937, 1939). Thirty years later, Heath et al. 
(1967a,b) reported the partial purification of a 
substance (taraxein) present in sera from schizo- 
phrenic patients that, when injected in monkeys 
as well as in normal human volunteers, pro- 
duced EEG and behavioral alterations analogous 
to those observed in schizophrenic patients. Since 
antibodies raised in sheep against human brain 
tissue injected into monkey cerebral ventricles 
produced similar EEG and behavioral changes, 
Heath proposed that taraxein could be an anti- 
brain antibody. In addition, using a fluorescent 
antibody-staining technique in studies of schizo- 
phrenic and normal postmortem brain, Heath 
and Krupp (1967) demonstrated the presence of 
antibrain globulins in schizophrenic sera. Table 
1 summarizes the salient features of a number 
of additional studies conducted by other inves- 
tigators over the past two decades designed to 
detect antibrain antibodies in schizophrenic sera. 
